Morgan Stanley Emerging Markets Debt Fund, Inc. (MSD)

COPENHAGEN, Denmark, December 19, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has been informed that MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA) will not exercise its option for Evaxion's Gonorrhea vaccine candidate EVX-B2. Consequently, Evaxion retains global rights to EVX-B2 and will look for another potential licensing partner.

NEW YORK--(BUSINESS WIRE)--Each of the Morgan Stanley closed-end funds listed below (the “Funds”) today declared the following dividends. RECORD DATE PAYABLE DATE 12/19/25 1/15/26       Name of Closed-End Fund     NYSE Ticker     Net Investment Income Per Share     Short-Term Capital Gains Per Share   Long-Term Capital Gains Per Share Morgan Stanley Emerging Markets Debt Fund, Inc. MSD $0.15* (Quarterly) -- -- Morgan Stanley Emerging Markets Domestic Debt Fund, Inc. EDD $0.13* (Quarterly) -- --.

Citi Trends delivered its fifth consecutive quarter of positive comps, underscoring sustained operational momentum and effective merchandising. CTRN projects 2027 sales of $900 million and EBITDA of $45 million, primarily via margin expansion rather than aggressive revenue growth. Despite execution, CTRN trades at 18x FY27 earnings, pricing in optimistic forward assumptions and leaving limited upside.

This month's top 10 closed-end funds offer an average yield of 9.25% and strong long-term performance across diverse asset classes. For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.

The Triple-Factor CEF Report screens over 400 funds for high yield (>6.5%), strong coverage (>90%), and discount to NAV, balancing yield, sustainability, and value. Top lists include funds with widest discounts, best z-scores, highest yields, and best combined metrics, offering potential for price appreciation and enhanced yields. Explore top lists for further research; these shortlists are not final buy/sell recommendations. Always verify coverage ratios with official fund documents.

LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), known as Merck in the U.S. and Canada, through a wholly owned subsidiary or a nominee, today announced that the High Court of Justice of England and Wales has approved the proposal for MSD to acquire Verona Pharma for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion (the “Transaction”).

NEW YORK--(BUSINESS WIRE)--Each of the Morgan Stanley closed-end funds listed below (the “Funds”) today declared the following dividends. RECORD DATE                   PAYABLE DATE 9/30/25   10/15/25 Name of Closed-End Fund NYSE Ticker  Net Investment Income Per Share Morgan Stanley Emerging Markets Debt Fund, Inc. MSD $0.17 Morgan Stanley Emerging Markets Domestic Debt Fund, Inc. EDD $0.12 For more information call: 1-800-231-2608. The amount of net investment income to be paid by the Funds is.

Tech innovators present solutions to tackle top workplace injury at NSC Safety Congress & Expo DENVER , Sept. 19, 2025 /PRNewswire/ -- The National Safety Council showcased 10 breakthrough technologies to help prevent musculoskeletal disorders (MSDs) at the fourth annual MSD Solutions Lab Safety Innovation Challenge.

MS Emerging Markets Debt Fund currently yields 10.11%, higher than most peers and indices, but is heavily invested in U.S. dollar-denominated bonds. MSD's recent underperformance is attributed to U.S. dollar weakness and lack of local currency exposure, making it less attractive than peer funds in the current environment. The fund's distribution is not fully covered by net investment income, and its discount to NAV is less attractive than historical averages and some peers like TEI.

Flexsteel presented very good 4Q25 (calendar 2Q25) results, with MSD growth in topline and operating margin leverage. However, growth is consistently decelerating, and the company might face more challenges in the near future because of tariffs. Flexsteel implemented tariffs surcharges of MSD/HSD in August, which might impact sales or gross margins.

MSD is not a good hedge against a weaker dollar, as it primarily holds USD-denominated emerging market debt. The fund now trades at a rare premium to NAV, with stretched valuations and historically tight EM credit spreads, making upside limited. Distribution currently exceeds yield-to-maturity, and while not a chronic over-distributor, the payout is not fully supported by earnings.

NEW YORK--(BUSINESS WIRE)--Each of the Morgan Stanley closed-end funds listed below (the “Funds”) today declared the following dividends. RECORD DATE PAYABLE DATE 6/30/25 7/15/25 Name of Closed-End Fund NYSE Ticker Net Investment Income Per Share Morgan Stanley Emerging Markets Debt Fund, Inc. MSD $0.19 Morgan Stanley Emerging Markets Domestic Debt Fund, Inc. EDD $0.12 The amount of net investment income to be paid by the Funds is determined in accordance with federal income tax regulations. It.

Evaxion has demonstrated impressive in-house capabilities for discovering and developing vaccine candidates for both infectious diseases and oncology indications. Partnership with MSD, albeit heavily backloaded, provides considerable validation of Evaxion's value. A potential option exercise by MSD expected later this year would bring in up to $10M. EVAX guides a cash runway into mid-2026, which could be extended into 2027 if MSD exercises options for both partnered candidates (not accounting for potential further business developments).

Emerging Market Debt offers higher spreads and a better risk/return profile compared to developed market debt, making it a valuable portfolio addition. Despite past headwinds like a strong USD, EMD's fundamentals are solid, with low default rates and improving sovereign reserves. MSD CEF outperforms peers and ETFs, offering a 12% yield with no leverage and a diversified, conservative strategy.

NEW YORK--(BUSINESS WIRE)--Each of the Morgan Stanley closed-end funds listed below (the “Funds”) today declared the following dividends. RECORD DATE   PAYABLE DATE 3/31/25   4/15/25 Name of Closed-End Fund   NYSE Ticker Net Investment Income Per Share Morgan Stanley Emerging Markets Debt Fund, Inc. MSD $0.22 Morgan Stanley Emerging Markets Domestic Debt Fund, Inc. EDD $0.16  For more information call: 1-800-231-2608. The amount of net investment income to be paid by the Funds is determined in.

The Morgan Stanley Emerging Markets Debt Fund offers high current income and exposure to emerging market debt, boasting a 13.27% yield, better than the bond indices. Despite potential risks from U.S. protectionist policies, the fund's well-diversified portfolio mitigates country-specific risks and has shown strong performance since the 2024 U.S. election. The fund's shares are currently trading at a 2.57% premium to net asset value, making it expensive compared to historical averages and peers.